HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Rhabdomyoma — Clinical Guidelines

Overview

Rhabdomyomas are benign cardiac tumors most commonly found in pediatric patients, often associated with tuberous sclerosis complex (TSC). They typically present in infancy and frequently regress spontaneously, though large or obstructive lesions may require intervention.

Diagnosis

Echocardiography: Primary imaging modality for diagnosis, identifying multiple tumors and assessing hemodynamic impact 1 5.

Cardiac MRI/CT: May be used for detailed tumor characterization and extent 1.

Genetic Testing: Considered in cases suspected of TSC association 1.

Postnatal Arrhythmia Prediction: Factors like tumor size and location may predict postnatal arrhythmias 2.

Management

Observation: Small, asymptomatic tumors often managed with close monitoring 1 4 8.

Medication:

- Sirolimus: Used for large tumors causing obstruction or arrhythmias 1. - Antiarrhythmic Agents: Employed to manage arrhythmias associated with rhabdomyomas 1.

Surgical Intervention: Indicated for symptomatic cases causing significant obstruction or intractable arrhythmias 7.

Electrophysiology Studies: May be necessary in cases with suspected accessory pathways or arrhythmias 6.

Special Populations

Pregnancy: Large fetal rhabdomyomas can necessitate emergent perinatal interventions due to hemodynamic compromise 1 3.

Pediatrics: Most common in infants; tumors often regress spontaneously but require close follow-up 1 4 8.

Sudden Infant Death Syndrome (SIDS): Rhabdomyomas can present as fatal arrhythmias in infants 9.

Key Recommendations

Regular Echocardiographic Monitoring: Essential for assessing tumor growth and hemodynamic impact in pediatric patients (Evidence: Moderate 1 4).

Surgical Intervention for Symptomatic Lesions: Recommended for cases causing significant obstruction or intractable arrhythmias (Evidence: Expert opinion 7).

Consider Sirolimus for Large Obstructive Tumors: May be effective in managing large fetal or pediatric rhabdomyomas causing hemodynamic compromise (Evidence: Weak 1).

Genetic Evaluation in Suspected TSC: Important for patients with rhabdomyomas to identify underlying TSC (Evidence: Moderate 1).

Electrophysiological Evaluation for Arrhythmias: Advised in cases with suspected accessory pathways or recurrent arrhythmias (Evidence: Weak 6).

References

1 Masilamani MSJ, Niaz T, Wackel PL, Horner JM, Cetta F, O'Leary PW et al.. Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents. Pediatric cardiology 2026. link 2 Ide T, Miyoshi T, Katsuragi S, Neki R, Kurosaki KI, Shiraishi I et al.. Prediction of postnatal arrhythmia in fetuses with cardiac rhabdomyoma. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2019. link 3 Sharma J, Inglis S, Cavalieri R, Udom-Rice I. Fetal demise secondary to massive rhabdomyoma in the early second trimester of pregnancy. Pediatric cardiology 2011. link 4 Nir A, Ekstein S, Nadjari M, Raas-Rothschild A, Rein AJ. Rhabdomyoma in the fetus: illustration of tumor growth during the second half of gestation. Pediatric cardiology 2001. link 5 Di Liang C, Ko SF, Huang SC. Echocardiographic evaluation of cardiac rhabdomyoma in infants and children. Journal of clinical ultrasound : JCU 2000. link28:8<381::aid-jcu2>3.0.co;2-d) 6 Van Hare GF, Phoon CK, Munkenbeck F, Patel CR, Fink DL, Silverman NH. Electrophysiologic study and radiofrequency ablation in patients with intracardiac tumors and accessory pathways: is the tumor the pathway?. Journal of cardiovascular electrophysiology 1996. link 7 Jacobs JP, Konstantakos AK, Holland FW, Herskowitz K, Ferrer PL, Perryman RA. Surgical treatment for cardiac rhabdomyomas in children. The Annals of thoracic surgery 1994. link91963-1) 8 Smythe JF, Dyck JD, Smallhorn JF, Freedom RM. Natural history of cardiac rhabdomyoma in infancy and childhood. The American journal of cardiology 1990. link91109-j) 9 Rigle DA, Dexter RD, McGee MB. Cardiac rhabdomyoma presenting as sudden infant death syndrome. Journal of forensic sciences 1989. link 10 Bruni C, Prioleau PG, Ivey HH, Nolan SP. New fine structural features of cardiac rhabdomyoma: report of a case. Cancer 1980. link46:9<2068::aid-cncr2820460927>3.0.co;2-c) 11 Silverman JF, Kay S, Chang CH. Ultrastructural comparison between skeletal muscle and cardiac rhabdomyomas. Cancer 1978. link42:1<189::aid-cncr2820420131>3.0.co;2-p) 12 Fenoglio JJ, MCAllister HA, Ferrans VJ. Cardiac rhabdomyoma: a clinicopathologic and electron microscopic study. The American journal of cardiology 1976. link90157-0)

Rhabdomyoma